| 1. |
- Simmen, K. A., et al.
(author)
-
Macrocylic inhibitors of hepatitis C virus
- 2012
-
Patent (pop. science, debate, etc.)abstract
- Inhibitors of HCV replication of formula (I)and the N-oxides, salts, and stereoisomers, whereineach dashed line represents an optional double bond;X is N, CH and where X bears a double bond it is C;R1 is —OR7, —NH—SO2R8;R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl;R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, C3-7cycloalkyl;R4 is aryl or Het; n is 3, 4, 5, or 6;R5 is halo, C1-6alkyl, hydroxy, C1-6alkoxy, phenyl, or Het;R6 is C1-6alkoxy, or dimethylamino;R7 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het;R8 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het;aryl is phenyl optionally substituted with one, two or three substituents;Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, and being optionally substituted with one, two or three substituents;pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.
|
|
| 2. |
|
|
| 3. |
- Ayesa, S., et al.
(author)
-
CYSTEINE PROTEASE INHIBITORS
- 2011
-
Patent (pop. science, debate, etc.)abstract
- Compounds of the formula IwhereinR1a is H; and R1b is C1-C6 alkyl, Carbocyclyl or Het; orR1a and R1b together define a saturated cyclic amine with 3-6 ring atoms;R2a and R2b are H, halo, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy; orR2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl;R3 is a branched C5-C10alkyl chain, C2-C4haloalkyl or C3-C7cycloalkylmethyl,R4 is Het, Carbocyclyl,optionally substituted as defined in the specification and pharmaceutically acceptable salts,hydrates and N-oxides thereof; are inhibitors of cathepsin S and have utility in the treatment of psoriasis, autoimmune disorders and other disorders such as asthma, arteriosclerosis, COPD and chronic pain.
|
|
| 4. |
- Lind, J., et al.
(author)
-
Parietal cortex activation predicts longitudinal memory decline in APOE ε4 carriers.
- 2006
-
In: NeuroReport. ; :17, s. 1683-1686
-
Journal article (pop. science, debate, etc.)abstract
- Apolipoprotein E-epsilon 4 is the main known genetic risk factor for Alzheimer’s disease. Functional abnormalities in the parietal cortex have been reported for Alzheimer’s disease patients and also for those at risk. Hence, a critical question is whether measurements of parietal cortex integrity may predict negative outcome among at- risk persons. We studied nondemented apolipo-protein E-epsilon 4 carriers and found a significant relationship between parietal blood-oxygen-level-dependent functional magnetic resonance imaging response during a word categorization task and subsequent episodic memory performance. Thus, the results show that parietal cortex alterations predict memory decline in nondemented apolipoprotein E-epsilon 4 carriers, and hence likely progression to Alzheimer’s disease.
|
|
| 5. |
- Magnuson, Martin, 1965-, et al.
(author)
-
Coherent and Incoherent Processes in resonant Photoemission
- 1997
-
In: Advanced Light Source. - California, USA : Ernest Orlando Lawrence Berkeley National Laboratory, University of California Berkeley. ; 65:2, s. 159-167
-
Book chapter (pop. science, debate, etc.)
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
- Antonov, D, et al.
(author)
-
HCV inhibiting macrocyclic phenylcarbamates
- 2008
-
Patent (pop. science, debate, etc.)abstract
- Compounds of the formula I: including a stereoisomer thereof, or an N-oxide, a pharmaceutically acceptable addition salt, or a pharmaceutically acceptable addition solvate thereof; useful as HCV inhibitors; processes for preparing these compounds as well as pharmaceutical compositions comprising these compounds as active ingredient.
|
|
| 10. |
|
|
